WCA
CPRX

Westover Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Westover Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$396K Buy
12,593
+1,974
+19% +$58.3K 0.07% 178
2026
Q1 		$263K Hold
10,619
– – 0.05% 209
2025
Q4 		$248K Hold
10,619
– – 0.05% 209
2025
Q3 		$209K Sell
10,619
-18,338
-63% -$377K 0.04% 214
2025
Q2 		$628K Buy
28,957
+16,674
+136% +$394K 0.13% 129
2025
Q1 		$298K Sell
12,283
-222
-2% -$5K 0.07% 194
2024
Q4 		$261K Sell
12,505
-270
-2% -$5.8K 0.06% 201
2024
Q3 		$254K Sell
12,775
-1,677
-12% -$31.1K 0.05% 215
2024
Q2 		$224K Sell
14,452
-18
-0.1% -$280 0.06% 195
2024
Q1 		$231K Sell
14,470
-70,106
-83% -$1.06M 0.07% 165
2023
Q4 		$1.42M Sell
84,576
-942
-1% -$12.9K 0.46% 54
2023
Q3 		$1,000K Sell
85,518
-17,379
-17% -$232K 0.36% 68
2023
Q2 		$1.38M Buy
+102,897
New +$1.48M 0.48% 52

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Westover Capital Advisors's CPRX Position: Q2 2026 in Review

Westover Capital Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 19% in Q2 2026, buying an estimated $58.3K and bringing the position to 12,593 shares worth $396K. The position accounts for 0.07% of the portfolio, ranked #178.

Westover Capital Advisors first reported a position in CPRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.42M in Q4 2023. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Westover Capital Advisors held 12,593 shares of Catalyst Pharmaceutical worth $396K as of Q2 2026.
  • Westover Capital Advisors bought 1,974 Catalyst Pharmaceutical shares in Q2 2026, an estimated $58.3K.
  • Catalyst Pharmaceutical made up 0.07% of Westover Capital Advisors's portfolio in Q2 2026, its #178 holding.
  • Westover Capital Advisors first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
  • Westover Capital Advisors's Catalyst Pharmaceutical position peaked at $1.42M in Q4 2023.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Westover Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.